Suven Life Sciences secures one product patents each for NCEs in Japan and USA

28 Jun 2013 Evaluate

Suven Life Sciences has been granted one product patent from Japan and one from USA corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these patents are valid through 2028 & 2029. With these new patents, the company has a total of six granted patents from Japan and, twelve granted product patents from USA.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.

Besides, these granted patents are exclusive intellectual property of the company and are achieved through the internal discovery research efforts. The products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

Suven Life Sciences is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets.

Suven Life Sciences Share Price

131.75 -3.65 (-2.70%)
23-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1814.50
Dr. Reddys Lab 1340.80
Cipla 1476.45
Lupin 2160.20
Zydus Lifesciences 972.95
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.